Biopharmaceutical benchmarks 2006

The rate of biopharmaceutical approvals has leveled off, but some milestones bode well for the future.

[1]  G. Heavner,et al.  Interaction of Polysorbate 80 with Erythropoietin: A Case Study in Protein–Surfactant Interactions , 2005, Pharmaceutical Research.

[2]  Shrikant Deshpande,et al.  Production of human monoclonal antibody in eggs of chimeric chickens , 2005, Nature Biotechnology.

[3]  M. Weitzman,et al.  Gene therapy: twenty-first century medicine. , 2005, Annual review of biochemistry.

[4]  Gary Walsh,et al.  Therapeutic insulins and their large-scale manufacture , 2005, Applied Microbiology and Biotechnology.

[5]  Dominic Gagné,et al.  Seminal vesicle production and secretion of growth hormone into seminal fluid , 1999, Nature Biotechnology.

[6]  R. Wind,et al.  High‐yield secretion of recombinant gelatins by Pichia pastoris , 1999, Yeast.

[7]  R. Buhmann,et al.  Aptamers—basic research, drug development, and clinical applications , 2005, Applied Microbiology and Biotechnology.

[8]  R. Rudolph,et al.  Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. , 2005, Trends in biotechnology.

[9]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[10]  B. Sullenger,et al.  Aptamers: an emerging class of therapeutics. , 2005, Annual review of medicine.

[11]  Anne Dallas,et al.  RNAi: a novel antisense technology and its therapeutic potential. , 2006, Medical science monitor : international medical journal of experimental and clinical research.

[12]  Asad U. Khan,et al.  Ribozyme: a clinical tool. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[13]  Tatiana Alvarez,et al.  GMP compliance for production of CB.Hep-1 monoclonal antibody as biological reagent , 2006 .

[14]  Zhao-hui Peng,et al.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. , 2005, Human gene therapy.

[15]  Gorka Orive,et al.  Drug delivery in biotechnology: present and future. , 2003, Current opinion in biotechnology.

[16]  Carole S Ben-Maimon,et al.  Biogenerics at the crossroads , 2006, Nature Biotechnology.

[17]  R. Ivarie,et al.  Competitive bioreactor hens on the horizon. , 2006, Trends in biotechnology.

[18]  Zhao-hui Peng,et al.  The genesis of gendicine: The story behind the first gene therapy , 2004 .

[19]  A. Plückthun,et al.  Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.

[20]  Huub Schellekens,et al.  Micelle-Associated Protein in Epoetin Formulations: A Risk Factor for Immunogenicity? , 2003, Pharmaceutical Research.

[21]  Gerhardt Attard,et al.  Making sense of antisense. , 2005, European journal of cancer.

[22]  D. Jarvis,et al.  Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production. , 2003, Virology.

[23]  Stacy Lawrence.  Biotech drug market steadily expands , 2005, Nature Biotechnology.

[24]  Huub Schellekens,et al.  Reaction to the paper: Interaction of Polysorbate 80 with Erythropoietin: A Case Study in Protein–Surfactant Interactions , 2006, Pharmaceutical Research.

[25]  L. Lim,et al.  Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure , 2005, Hematology.

[26]  Carole S Ben-Maimon.  Point: Why biogenerics make sense , 2006, Nature Biotechnology.

[27]  A. Pavlou,et al.  Research paper The therapeutic antibodies market to 2008 , 2005 .

[28]  Youwei Jiang,et al.  Optimization of humanized IgGs in glycoengineered Pichia pastoris , 2006, Nature Biotechnology.

[29]  Jeffrey L. Fox.  Sandoz sues FDA over delay in first biogeneric approval , 2005, Nature Biotechnology.

[30]  C. Sheridan,et al.  TeGenero fiasco prompts regulatory rethink , 2006, Nature Biotechnology.

[31]  Gary P. Martin,et al.  Dermal and Transdermal Drug Delivery Systems: Current and Future Prospects , 2006, Drug delivery.

[32]  C. Diliberti,et al.  The best targets for biogenerics , 2006 .

[33]  J. Hamman,et al.  Oral delivery of peptide drugs: barriers and developments. , 2005, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[34]  James M. Wilson.  Gendicine: The First Commercial Gene Therapy Product; Chinese Translation of Editorial , 2005 .

[35]  S. Wildt,et al.  The humanization of N-glycosylation pathways in yeast , 2005, Nature Reviews Microbiology.

[36]  王姮,et al.  Inhaled insulin , 2005 .

[37]  T. Kjeldsen,et al.  Yeast secretory expression of insulin precursors , 2000, Applied Microbiology and Biotechnology.

[38]  Paul Chamberlain,et al.  Biopharmaceutical production in plants: problems, solutions and opportunities. , 2005, Trends in biotechnology.

[39]  James M. Wilson,et al.  Gendicine: the first commercial gene therapy product. , 2005, Human gene therapy.

[40]  Wenjuan Yang,et al.  Transdermal protein delivery by a coadministered peptide identified via phage display , 2006, Nature Biotechnology.

[41]  Gary Walsh,et al.  Biopharmaceutical benchmarks , 2000, Nature Biotechnology.

[42]  T. Gerngross,et al.  Advances in the production of human therapeutic proteins in yeasts and filamentous fungi , 2004, Nature Biotechnology.

[43]  A. Pavlou,et al.  Recombinant protein therapeutics—success rates, market trends and values to 2010 , 2004, Nature Biotechnology.

[44]  Michael Butler,et al.  Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals , 2005, Applied Microbiology and Biotechnology.

[45]  Gary Walsh,et al.  Biopharmaceutical benchmarks—2003 , 2003, Nature Biotechnology.

[46]  A. Pavlou,et al.  The therapeutic antibodies market to 2008. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[47]  Qingsheng Qi,et al.  Modification of Plant N-Glycans Processing: The Future of Producing Therapeutic Protein by Transgenic Plants , 2005 .

[48]  S. Jana,et al.  RNA interference: potential therapeutic targets , 2004, Applied Microbiology and Biotechnology.